Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Foamix, a clinical-stage, specialty pharmaceutical company, has announced that the US Patent and Trademark Office (USPTO) has issued five new patents covering its technologies.
Subscribe to our email newsletter
Foamix now has a total of 25 issued US Patents, 61 issued worldwide and 126 patents pending.
These new patents, which were issued between August 2013 and January 2014, cover the composition of matter of various kinds of pharmaceutical and cosmeceutical foams; devices for dispensing them; and a novel platform of the topical foam compositions that stabilize unstable drugs such as minocycline and doxycycline, which would otherwise be unstable with other topical carriers.
Foamix CEO Dov Tamarkin noted that establishing broad and robust patent portfolios in dermatology foams and minocycline/doxycycline is a key part of its strategy.
"These new patents strengthen our position as the leading company worldwide specializing in developing foam based pharmaceutical products.
"As the intellectual property technology leader in foams, Foamix has licensed various forms of its patented foams to Bayer, Merz, Actavis, Round Table Group and Arkin Dermatology, all of which are in Phase 2 or Phase 3 clinical trials using their own active pharmaceutical ingredients," Tamarkin added.